IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/14/2019 |
| Start Date: | February 2010 |
| End Date: | February 2020 |
The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma
The purpose of this study is to determine which participants with melanoma have a better
response to IL-2 and to identify markers that may predict response to IL-2 by collecting
participant information (for example; cancer diagnosis and history, prior treatments for
cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after
treatment.
response to IL-2 and to identify markers that may predict response to IL-2 by collecting
participant information (for example; cancer diagnosis and history, prior treatments for
cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after
treatment.
Original tumor slides will be collected to identify tumor markers that may predict responses
to treatment. Blood samples will be obtained prior to treatment with IL-2.
to treatment. Blood samples will be obtained prior to treatment with IL-2.
Inclusion Criteria:
- Malignant melanoma that is metastatic or unresectable
- Eligible to receive high-dose IL-2
- Tissue block available with adequate tumor to perform RNA extraction and DASL analysis
Exclusion Criteria:
- Prior immunotherapy for unresectable or metastatic disease
- Untreated brain metastases, leptomeningeal disease, or seizure disorder
We found this trial at
1
site
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
